fresenius se & co. kgaa - FSNUY

FSNUY

Close Chg Chg %
10.76 0.18 1.71%

Closed Market

10.94

+0.18 (1.71%)

Volume: 27.48K

Last Updated:

Apr 3, 2025, 3:53 PM EDT

Company Overview: fresenius se & co. kgaa - FSNUY

FSNUY Key Data

Open

$11.28

Day Range

10.94 - 11.28

52 Week Range

6.74 - 11.28

Market Cap

$24.15B

Shares Outstanding

2.25B

Public Float

N/A

Beta

0.83

Rev. Per Employee

N/A

P/E Ratio

47.42

EPS

$0.23

Yield

0.00%

Dividend

$0.17

EX-DIVIDEND DATE

May 18, 2023

SHORT INTEREST

N/A

AVERAGE VOLUME

43.61K

 

FSNUY Performance

1 Week
 
-1.47%
 
1 Month
 
-2.47%
 
3 Months
 
24.24%
 
1 Year
 
56.61%
 
5 Years
 
12.02%
 

FSNUY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About fresenius se & co. kgaa - FSNUY

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

FSNUY At a Glance

Fresenius SE & Co. KGaA
Else-Kröner-Strasse 1
Bad Homburg, Hessen 61352
Phone 49-6172-608-0 Revenue 23.62B
Industry Hospital/Nursing Management Net Income 509.48M
Sector Health Services Employees 176,486
Fiscal Year-end 12 / 2025
View SEC Filings

FSNUY Valuation

P/E Current 47.417
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 38.403
Price to Sales Ratio 0.828
Price to Book Ratio 0.967
Price to Cash Flow Ratio 7.067
Enterprise Value to EBITDA 9.741
Enterprise Value to Sales 1.356
Total Debt to Enterprise Value 0.439

FSNUY Efficiency

Revenue/Employee 133,815.454
Income Per Employee 2,886.781
Receivables Turnover 4.137
Total Asset Turnover 0.497

FSNUY Liquidity

Current Ratio 1.271
Quick Ratio 0.985
Cash Ratio 0.253

FSNUY Profitability

Gross Margin 24.632
Operating Margin 8.409
Pretax Margin 6.183
Net Margin 2.157
Return on Assets 2.37
Return on Equity 5.468
Return on Total Capital 3.287
Return on Invested Capital 3.362

FSNUY Capital Structure

Total Debt to Total Equity 69.476
Total Debt to Total Capital 40.995
Total Debt to Total Assets 31.176
Long-Term Debt to Equity 55.291
Long-Term Debt to Total Capital 32.625
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fresenius Se & Co. Kgaa - FSNUY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
43.82B 42.71B 24.11B 23.62B
Sales Growth
+5.97% -2.55% -43.55% -2.04%
Cost of Goods Sold (COGS) incl D&A
32.23B 31.65B 18.64B 17.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.13B 3.08B 1.60B 1.30B
Depreciation
- - 2.64B 2.52B
-
Amortization of Intangibles
- - 489.34M 563.32M
-
COGS Growth
+8.90% -1.80% -41.11% -4.51%
Gross Income
11.59B 11.06B 5.47B 5.82B
Gross Income Growth
-1.41% -4.62% -50.55% +6.38%
Gross Profit Margin
+26.46% +25.89% +22.68% +24.63%
2021 2022 2023 2024 5-year trend
SG&A Expense
7.34B 7.94B 4.07B 3.83B
Research & Development
914.85M 884.92M 657.32M 693.36M
Other SG&A
6.42B 7.05B 3.41B 3.14B
SGA Growth
+4.31% +8.16% -48.76% -5.80%
Other Operating Expense
- - - -
-
Unusual Expense
(656.00M) (86.18M) 112.44M 12.98M
EBIT after Unusual Expense
4.91B 3.21B 1.29B 1.97B
Non Operating Income/Expense
42.55M 403.57M 70.27M 74.64M
Non-Operating Interest Income
140.66M 194.43M 127.57M 122.23M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
747.01M 724.12M 572.99M 587.36M
Interest Expense Growth
-12.63% -3.06% -20.87% +2.51%
Gross Interest Expense
747.01M 724.12M 572.99M 589.52M
Interest Capitalized
- - - 2.16M
-
Pretax Income
4.21B 2.89B 785.97M 1.46B
Pretax Income Growth
-0.96% -31.40% -72.77% +85.79%
Pretax Margin
+9.60% +6.76% +3.26% +6.18%
Income Tax
984.59M 732.53M 515.69M 563.56M
Income Tax - Current - Domestic
92.19M 81.98M 120.00M 42.19M
Income Tax - Current - Foreign
793.11M 781.92M 411.91M 486.76M
Income Tax - Deferred - Domestic
22.46M 72.52M 63.79M 46.51M
Income Tax - Deferred - Foreign
76.83M (203.89M) (80.00M) (11.90M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.33B 2.22B 257.31M 937.83M
Minority Interest Expense
1.18B 782.98M (124.33M) (189.30M)
Net Income
2.15B 1.44B 381.63M 1.13B
Net Income Growth
+10.43% -32.90% -73.53% +195.34%
Net Margin Growth
+4.90% +3.38% +1.58% +4.77%
Extraordinaries & Discontinued Operations
- - (1.02B) (617.65M)
-
Discontinued Operations
- - (1.02B) (617.65M)
-
Net Income After Extraordinaries
2.15B 1.44B (642.18M) 509.48M
Preferred Dividends
- - - -
-
Net Income Available to Common
2.15B 1.44B (642.18M) 509.48M
EPS (Basic)
0.9626 0.6423 -0.285 0.2261
EPS (Basic) Growth
+10.30% -33.27% -144.37% +179.33%
Basic Shares Outstanding
2.23B 2.25B 2.25B 2.25B
EPS (Diluted)
0.9625 0.6423 -0.285 0.2261
EPS (Diluted) Growth
+10.35% -33.27% -144.37% +179.33%
Diluted Shares Outstanding
2.23B 2.25B 2.25B 2.25B
EBITDA
7.39B 6.20B 3.00B 3.29B
EBITDA Growth
-5.51% -15.99% -51.67% +9.65%
EBITDA Margin
+16.85% +14.53% +12.44% +13.92%

Snapshot

Average Recommendation BUY Average Target Price 12.253
Number of Ratings 17 Current Quarters Estimate 0.211
FY Report Date 06 / 2025 Current Year's Estimate 0.888
Last Quarter’s Earnings 0.208 Median PE on CY Estimate N/A
Year Ago Earnings 0.819 Next Fiscal Year Estimate 0.984
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 13 14
Mean Estimate 0.21 0.21 0.89 0.98
High Estimates 0.23 0.26 0.93 1.05
Low Estimate 0.17 0.20 0.84 0.85
Coefficient of Variance 10.57 11.80 3.73 5.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 12
OVERWEIGHT 3 3 3
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Fresenius Se & Co. Kgaa in the News